Novel screening tool aids search for curative kidney treatment

Scientists have developed a screening tool for identifying compounds that restore functionality of the protein that is dysfunctional in Alport syndrome.

Credit: Jubal Harshaw/

It is hoped that the finding will ultimately lead to the development of corrective therapeutics for  Alport syndrome, and other, currently incurable hereditary condition.

Alport Syndrome is a hereditary kidney disease that affects the glomerular basement membrane within the filtration system of the kidney. This allows blood and proteins to escape into the urine and ultimately leads to end-stage kidney disease and hearing loss.

Patients usually develop chronic kidney failure by the age of 25 years. Although there are some treatments available that can slow the progression of Alport Syndrome, such as ACE inhibitors, a corrective treatment has yet to be found.

The causal factor in Alport Syndrome is a genetic mutation in the gene encoding chains of collagen IV that prevents them associating into a trimer.

Since trimer formation is necessary for collagen IV to be incorporated into the glomerular basement membrane in the kidney, the mutation results in the membrane becoming leaky.

It no longer forms a physical barrier against leakage of blood components into the urine. In order to cure Alport Syndrome, a treatment is needed to restore collagen IV functionality.

The first step in the development of such a treatment is to identify potential drug candidates by screening compounds for their ability to correct the aberrant collagen IV function. Currently, there is not a system in place for such screening, and so it is a costly and labour-intensive process.

Researchers at Kumamoto University have developed a novel methodology for rapidly screening numerous compounds for their ability to enable mutated collagen chains to form trimers. They fused the collagen chains to fragments of the enzyme nanoluciferase.

On trimer formation luminescence occurs, which provides a measurable indicator of collagen IV functionality. The system detects collagen IV functionality with higher sensitivity than has been achieved previously and makes it possible to analyze several potential drug candidates simultaneously.

This research should provide a pathway to develop drugs for hereditary diseases, such as Alport Syndrome, that are currently incurable."

Hirofumi Kai, Professor at Kumamoto University

Kate Bass

Written by

Kate Bass

Kate graduated from the University of Newcastle upon Tyne with a biochemistry B.Sc. degree. She also has a natural flair for writing and enthusiasm for scientific communication, which made medical writing an obvious career choice. In her spare time, Kate enjoys walking in the hills with friends and travelling to learn more about different cultures around the world.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bass, Kate. (2019, June 24). Novel screening tool aids search for curative kidney treatment. News-Medical. Retrieved on July 16, 2024 from

  • MLA

    Bass, Kate. "Novel screening tool aids search for curative kidney treatment". News-Medical. 16 July 2024. <>.

  • Chicago

    Bass, Kate. "Novel screening tool aids search for curative kidney treatment". News-Medical. (accessed July 16, 2024).

  • Harvard

    Bass, Kate. 2019. Novel screening tool aids search for curative kidney treatment. News-Medical, viewed 16 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease